{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["104(2)"],"submitter":["Matsuda R"],"pubmed_abstract":["<h4>Background</h4>The aim of this study is to find a novel molecular target based on chromosomal alteration and array-based gene expression analyses in bladder cancer (BC). We investigated a cancer testis antigen, LY6K, which is located on chromosome 8q24.3.<h4>Methods</h4>Five BC cell lines were subjected to high-resolution array-comparative genomic hybridisation with 244 000 probes. The expression levels of LY6K mRNA were evaluated in BC cell lines and clinical BC specimens by real-time reverse transcription-PCR. The cell lines were subjected to fluorescence in situ hybridisation of LY6K. Cell viability was evaluated by cell growth, wound healing, and matrigel invasion assays.<h4>Results</h4>Typical gained loci (P<0.0001) at 6p21.33-p21.32, 8q24.3, 9q34.13, 11q13.1-q14.1, 12q13.12-q13.1"],"journal":["British journal of cancer"],"pagination":["376-86"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3031884"],"repository":["biostudies-literature"],"pubmed_title":["LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling."],"pmcid":["PMC3031884"],"pubmed_authors":["Nakagawa M","Toki K","Tatarano S","Sugimoto T","Matsuda R","Kawakami K","Yoshino H","Kawahara K","Chiyomaru T","Nishiyama K","Enokida H","Kikkawa N","Seki N","Uchida Y"],"additional_accession":[]},"is_claimable":false,"name":"LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.","description":"<h4>Background</h4>The aim of this study is to find a novel molecular target based on chromosomal alteration and array-based gene expression analyses in bladder cancer (BC). We investigated a cancer testis antigen, LY6K, which is located on chromosome 8q24.3.<h4>Methods</h4>Five BC cell lines were subjected to high-resolution array-comparative genomic hybridisation with 244 000 probes. The expression levels of LY6K mRNA were evaluated in BC cell lines and clinical BC specimens by real-time reverse transcription-PCR. The cell lines were subjected to fluorescence in situ hybridisation of LY6K. Cell viability was evaluated by cell growth, wound healing, and matrigel invasion assays.<h4>Results</h4>Typical gained loci (P<0.0001) at 6p21.33-p21.32, 8q24.3, 9q34.13, 11q13.1-q14.1, 12q13.12-q13.1","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Jan","modification":"2025-04-03T22:18:30.409Z","creation":"2019-03-27T00:38:34Z"},"accession":"S-EPMC3031884","cross_references":{"pubmed":["21063397"],"doi":["10.1038/sj.bjc.6605990"]}}